REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

Tue 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE0889Da&default-theme=true

RNS Number : 0889D  GSK PLC  05 May 2026

 

GSK plc (the 'Company')

 

2026 Award under the Deferred Investment Award Programme

Notional Award

 

On 1 May 2026, the Company granted an award over notional Ordinary Shares to
Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under
the GlaxoSmithKline Deferred Investment Award programme. The award has been
granted upon Ms Parry joining GSK as Chief People Officer and a newly
appointed Executive Committee member.

 

Under the programme, awards are made over notional Ordinary Shares with
vesting over a specified period to provide long-term alignment with
shareholders. Vesting is subject to the PDMR not having served the Company
notice or having been terminated by the Company for cause. Dividends will
accrue on the award during the vesting period. On vesting, the award will be
paid in cash. The award will vest in two increments: 34.22% of the award will
vest on 31 August 2028 and 65.78% of the award will vest on 31 August 2029.

 

Executive Directors are not eligible to receive awards under the programme.

 

Transaction notification

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Roanne Parry
 b)  Position/status                          Chief People Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                A restricted award of notional Ordinary Shares under the Company's Deferred
                                              Investment Award programme.

 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   £19.01               35,507.628

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-05-01
 f)  Place of the transaction                 N/A

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSSAFFIEMSEFI



            Copyright 2019 Regulatory News Service, all rights reserved